Jeffry Bieber, MD
Rheumatology · Johnson City, TNNPI 1831294891
Payments from drug & device makers
Across 709 payments — averaging $62.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$20K
- AbbVie$19K
- Pfizer$1K
- AstraZeneca$819
- Johnson & Johnson$677
- Novartis$669
- plus $3K from 25 others
What the payments were for
- Speaking & faculty fees$15,07555%
- Travel & lodging$8843%
- Food & beverage$11,10941%
- Education$1150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 171 | $20,052 |
| AbbVie | 190 | $18,668 |
| Pfizer | 92 | $1,070 |
| AstraZeneca(2 entities) | 41 | $819 |
| Johnson & Johnson(2 entities) | 31 | $677 |
| Novartis | 43 | $669 |
| GSK | 25 | $454 |
| Lilly USA, LLC | 13 | $282 |
| UCB, Inc. | 9 | $182 |
| Boehringer Ingelheim | 6 | $165 |
| Mallinckrodt Hospital Products Inc. | 9 | $161 |
| Actelion Pharmaceuticals US, Inc. | 6 | $154 |
| Sandoz | 6 | $147 |
| Aurinia Pharma U.S., Inc. | 8 | $135 |
| Organon | 8 | $133 |
| Bristol Myers Squibb | 13 | $108 |
| Kiniksa Pharmaceuticals International, PLC | 4 | $104 |
| Sobi, Inc | 5 | $103 |
| E.r. Squibb & Sons, L.L.C. | 6 | $88 |
| Regeneron Healthcare Solutions, Inc. | 3 | $71 |
| Kyowa Kirin, Inc. | 3 | $70 |
| Fresenius Kabi USA, LLC | 3 | $70 |
| Radius Health, Inc. | 3 | $68 |
| Genentech USA, Inc. | 3 | $58 |
| United Therapeutics Corporation | 2 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $28 |
| Mallinckrodt Enterprises LLC | 1 | $20 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Scilex Pharmaceuticals Inc. | 1 | $15 |
| Sanofi | 1 | $14 |
| Zyla Life Sciences, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$44,658 in reported general payments places this provider in the 80th percentile of 127 rheumatology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Enbrel SureclickEtanercept | 318 | $2,289,044 |
| Humira(Cf) PenAdalimumab | 183 | $1,273,777 |
| Orencia ClickjectAbatacept | 151 | $827,948 |
| RinvoqUpadacitinib | 114 | $706,949 |
| Skyrizi PenRisankizumab-Rzaa | 31 | $632,730 |
| Actemra ActpenTocilizumab | 87 | $387,788 |
| OtezlaApremilast | 67 | $292,679 |
| Xeljanz XrTofacitinib Citrate | 47 | $255,833 |
| Cosentyx Unoready PenSecukinumab | 26 | $218,576 |
| Cimzia (2 Pack)Certolizumab Pegol | 35 | $201,199 |
| HumiraAdalimumab | 28 | $186,457 |
| Humira PenAdalimumab | 21 | $139,050 |
| BenlystaBelimumab | 28 | $138,277 |
| Humira(Cf)Adalimumab | 15 | $98,961 |
| Cosentyx Sensoready PenSecukinumab | 13 | $96,808 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Humira, Humira(Cf) | $18,668 | $992,367157 claims |
| AmgenOtezla, Enbrel | $20,052 | $382,49379 claims |
| UCB, Inc.Cimzia (2 Pack) | $182 | $201,19935 claims |
| GSKBenlysta | $454 | $138,27728 claims |
| SanofiKevzara | $14 | $90,82821 claims |
| Johnson & JohnsonSimponi | $677 | $79,49813 claims |
| Lilly USA, LLCForteo | $282 | $60,25515 claims |
| Scilex Pharmaceuticals Inc.Colchicine | $15 | $1,35817 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 127 rheumatology providers in Tennessee.
Other rheumatology in Johnson City
- Gerald FalascaJohnson City$24K
- Jacob AelionJackson$13.2M
- Ramesh GuptaMemphis$5.5M
- Joseph HuffstutterHixson$832K
- Marcus OwenMurfreesboro$594K
- Brett SmithKnoxville$587K
- Satish OdhavJackson$527K
- Erin WilfongNashville$388K
- Robert CollinsNashville$383K
- Jason SpringerNashville$363K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.